Cyclosporine experience in nephrotic syndrome

Area of Science:

• Pediatric Nephrology
• Clinical Pharmacology

Background:

• Nephrotic syndrome is a complex kidney disorder affecting children.
• Steroid-dependent and steroid-resistant forms pose treatment challenges.
• Cyclosporine (CyA) is an immunosuppressant with potential applications.

Purpose of the Study:

• To evaluate the efficacy and safety of Cyclosporine (CyA) in children with primary nephrotic syndrome.
• To analyze treatment outcomes in relation to steroid responsiveness and histopathology.

Main Methods:

• A cohort of 35 children with nephrotic syndrome received oral CyA (6-7 mg/kg/day).
• Patients were monitored for efficacy (remission, relapse) and toxicity (hepatotoxicity, nephrotoxicity).
• Follow-up averaged 2.55 years, with a minimum of 8 weeks of CyA therapy.

Main Results:

• 31 patients completed the study; responses varied (no response, good, partial, CyA dependence, infrequent relapsers).
• 16 patients achieved complete remission on CyA, but 16 showed CyA dependence (relapse within 3 months).
• Response correlated more with steroid-responsiveness than histopathology; CyA was generally well tolerated.

Conclusions:

• Cyclosporine (CyA) is a viable therapeutic option for children with steroid-dependent or steroid-resistant nephrotic syndrome and normal renal function.
• Longer durations of CyA therapy might be indicated to achieve more sustained remission.